未治疗HIV-1感染者中药物耐药 minority 变异的流行率:Sanger测序检测传播性耐药与否的比较
该研究针对33例孤立NNRTI相关传播性耐药者和49例匹配对照,用Sanger测序检测minority变异。两组总体及NRTI相关minority耐药突变比例相似,提示孤立NNRTI传播性耐药可能不是非NNRTI方案治疗病毒学失败的危险因素。
要点
- 孤立NNRTI传播性耐药者与对照的minority耐药突变比例相似。
- 提示该类耐药可能不增加非NNRTI方案病毒学失败风险。
- 研究样本量有限,结论需谨慎解读。
核心结论
- 孤立NNRTI相关传播性耐药可能不是非NNRTI方案治疗病毒学失败的危险因素。
研究设计与样本
- 比较33例孤立NNRTI相关传播性耐药者与49例匹配对照的minority变异耐药突变。
主要发现
- 两组总体minority变异耐药突变比例相似。
- 两组NRTI相关minority变异耐药突变比例相似。
临床怎么用
- 对孤立NNRTI传播性耐药者选用非NNRTI方案时,minority变异监测的额外价值有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Minority variant human immunodeficiency virus type 1 (HIV-1) nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance mutations are associated with an increased risk of virological failure during treatment with NNRTI-containing regimens. To determine whether individuals to whom variants with isolated NNRTI-associated drug resistance were transmitted are at increased risk of virological failure during treatment with a non-NNRTI-containing regimen, we identified minority variant resistance mutations in 33 individuals with isolated NNRTI-associated transmitted drug resistance and 49 matched controls. We found similar proportions of overall and nucleoside reverse transcriptase inhibitor-associated minority variant resistance mutations in both groups, suggesting that isolated NNRTI-associated transmitted drug resistance may not be a risk factor for virological failure during treatment with a non-NNRTI-containing regimen.
引用
- Clutter DS, Zhou S, Varghese V, et al. Prevalence of Drug-Resistant Minority Variants in Untreated HIV-1-Infected Individuals With and Those Without Transmitted Drug Resistance Detected by Sanger Sequencing. J Infect Dis. 2017. PMID: 28859436. doi:10.1093/infdis/jix338
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。